文献速递前列腺增生与排尿功能障碍泌尿系感染

脂肪酸酰胺水解酶抑制剂治疗男性慢性前列腺炎/慢性盆腔疼痛综合征:一项适应性双盲随机对照试验

Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial.
PubMed 文献 · Urology · 2017-02-27

这项适应性双盲安慰剂对照试验将239例中重度慢性前列腺炎/慢性盆腔疼痛综合征男性患者随机分配,接受ASP3652(25、75、150或300 mg每日两次,或300 mg每日一次)或安慰剂治疗12周。研究因无效而提前终止:25 mg组主要终点美国国立卫生研究院慢性前列腺炎症状指数总分降幅最大(7.0分),但安慰剂组平均降幅为7.3分(差值0.3,95%CI:-1.9,2.6)。所有ASP3652组的排尿结局较安慰剂改善,安全性相当。

要点

  • ASP3652总体安全且耐受性良好,但对慢性前列腺炎/慢性盆腔疼痛综合征疼痛症状未显示疗效。
  • 25 mg组美国国立卫生研究院慢性前列腺炎症状指数总分降幅7.0分,安慰剂组7.3分,差值0.3(95%CI:-1.9,2.6)。
  • 300 mg每日两次组排尿频率较安慰剂减少1.10次/24小时(95%CI:-2.0,-0.2)。

核心结论

  • ASP3652总体安全且耐受性良好,但对慢性前列腺炎/慢性盆腔疼痛综合征患者的疼痛症状未显示疗效。
  • 结果提示抑制脂肪酸酰胺水解酶可能减轻下尿路症状,需要在下尿路功能障碍患者中开展专门研究来证实。

研究设计与样本

  • 适应性、随机、双盲、安慰剂对照研究,纳入中重度慢性前列腺炎/慢性盆腔疼痛综合征成年男性患者。
  • 治疗12周,口服ASP3652 25、75、150或300 mg每日两次,或300 mg每日一次,或安慰剂。
  • 采用贝叶斯模型进行随机化的适应性前瞻性建模、研究继续决策和疗效变量分析。
  • 计划期中分析时239例患者被随机分配,226例纳入意向治疗集,研究因无效而停止。

主要发现

  • 25 mg组主要终点美国国立卫生研究院慢性前列腺炎症状指数总分降幅最大(7.0分),安慰剂组平均降幅为7.3分(差值0.3,95%CI:-1.9,2.6)。
  • 所有ASP3652组的排尿结局较安慰剂改善,例如300 mg每日两次组排尿频率较安慰剂减少1.10次/24小时(95%CI:-2.0,-0.2)。
  • 安全性结局在各治疗组间相当。

局限性

  • 研究因无效在计划期中分析时停止。
  • 结果提示脂肪酸酰胺水解酶抑制可能减轻下尿路症状,但需要在排尿功能障碍患者中开展专门研究来证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effect of a peripherally active fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on safety and efficacy outcomes in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Inhibition of FAAH is hypothesized to reduce the excitability of urinary tract afferents including nociceptors. MATERIALS AND METHODS: In this adaptive, randomized, double-blind, placebo-controlled study, adult male patients with moderate to severe CP/CPPS were treated for 12 weeks with an oral dose of ASP3652 (25, 75, 150, or 300 mg twice daily, or 300 mg once daily), or placebo. A Bayesian model was used for adaptive prospective modeling of randomization, study continuation decisions, and analysis of the efficacy variables. RESULTS: The study was stopped for futility at preplanned interim analysis when 239 patients were randomized (226 were included in the intention-to-treat set): the 25 mg group showed the largest reduction of the primary end point National Institutes of Health Chronic Prostatitis Symptom Index total score (7.0 points), but the placebo group showed a mean reduction of 7.3 points (difference: 0.3 [95% confidence interval: -1.9, 2.6]). Micturition outcomes improved compared with placebo in all ASP3652 groups; for example, in the 300 mg twice daily group, voiding frequency decreased by -1.10 (95% CI: -2.0, -0.2) voids/24 hours vs placebo. Safety outcomes were comparable across the treatment groups. CONCLUSION: ASP3652 was generally safe and well-tolerated. It did not show efficacy on pain symptoms in patients with CP/CPPS. However, the results indicate that FAAH inhibition may attenuate lower urinary tract symptoms. Dedicated studies in patients with lower urinary tract dysfunction are needed to confirm this.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Wagenlehner FME, van Till JWO, Houbiers JGA, et al. Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial. Urology. 2017. PMID: 28254462. doi:10.1016/j.urology.2017.02.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。